S
Stephan Probst
Researcher at McGill University
Publications - 85
Citations - 4287
Stephan Probst is an academic researcher from McGill University. The author has contributed to research in topics: Prostate cancer & Docetaxel. The author has an hindex of 19, co-authored 73 publications receiving 2960 citations. Previous affiliations of Stephan Probst include Jewish General Hospital.
Papers
More filters
Journal ArticleDOI
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
Salah-Eddin Al-Batran,Nils Homann,Claudia Pauligk,Thorsten Oliver Goetze,Johannes Meiler,Stefan Kasper,Hans-Georg Kopp,Frank Mayer,Georg Martin Haag,Kim Barbara Luley,U. Lindig,Wolff Schmiegel,Michael Pohl,Jan Stoehlmacher,Gunnar Folprecht,Stephan Probst,Nicole Prasnikar,Wolfgang Fischbach,Rolf Mahlberg,Jörg Trojan,Michael Koenigsmann,Uwe M. Martens,Peter C. Thuss-Patience,Matthias Egger,Andreas Block,Volker Heinemann,Gerald Illerhaus,Markus Moehler,Michael Schenk,Frank Kullmann,Dirk M Behringer,Michael Heike,Daniel Pink,Christian Teschendorf,Carmen Löhr,Helga Bernhard,G. Schuch,Volker Rethwisch,Ludwig Fischer von Weikersthal,Jörg T. Hartmann,Michael Kneba,Severin Daum,Karsten Schulmann,Jörg Weniger,Sebastian Belle,Timo Gaiser,Fuat Oduncu,Martina Güntner,Wael Hozaeel,Alexander Reichart,Elke Jäger,Thomas Kraus,Stefan Mönig,Wolf O. Bechstein,Martin Schuler,Harald Schmalenberg,Ralf Hofheinz,Flot Aio Investigators +57 more
TL;DR: In this article, the safety and efficacy of the docetaxel-based triplet FLOT (fluorouracil plus leucovorin, oxaliplatin, and doceteaxel) as a perioperative therapy for patients with locally advanced, resectable tumours was reported.
Journal ArticleDOI
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie
Salah-Eddin Al-Batran,Joerg T. Hartmann,Stephan Probst,Harald Schmalenberg,S. Hollerbach,Ralf Hofheinz,Volker Rethwisch,G. Seipelt,Nils Homann,Gerhard Wilhelm,Gunter Schuch,Jan Stoehlmacher,Hans Günter Derigs,Susanna Hegewisch-Becker,Johannes Grossmann,Claudia Pauligk,Akin Atmaca,Carsten Bokemeyer,Alexander Knuth,Elke Jäger +19 more
TL;DR: In older adult patients, FLO also seemed to be associated with improved efficacy in patients with advanced gastric cancer, and in patients older than 65 years, this study found that FLO reduced toxicity as compared with FLP.
Journal ArticleDOI
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.
Salah-Eddin Al-Batran,Ralf Hofheinz,Claudia Pauligk,Hans-Georg Kopp,Georg Martin Haag,Kim Barbara Luley,Johannes Meiler,Nils Homann,Sylvie Lorenzen,Harald Schmalenberg,Stephan Probst,Michael Koenigsmann,Matthias Egger,Nicole Prasnikar,Karel Caca,Jörg Trojan,Uwe M. Martens,Andreas Block,Wolfgang Fischbach,Rolf Mahlberg,Michael R. Clemens,Gerald Illerhaus,Katja Zirlik,Dirk Behringer,Wolff Schmiegel,Michael Pohl,Michael Heike,Ulrich Ronellenfitsch,Martin Schuler,Wolf O. Bechstein,Alfred Königsrainer,Timo Gaiser,Peter Schirmacher,Wael Hozaeel,Alexander Reichart,Thorsten Oliver Goetze,Mark Sievert,Elke Jäger,Stefan Mönig,Andrea Tannapfel +39 more
TL;DR: Findings from the phase 2 part of the FLOT4 trial, which compared histopathological regression in patients treated with a docetaxel-based triplet chemotherapy versus an anthracycline-based doublet chemotherapy before surgical resection, suggest FLOT was associated with significantly higher proportions of patients achieving pathological complete regression than was ECF/ECX.
Journal ArticleDOI
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial
Salah-Eddin Al-Batran,Nils Homann,Claudia Pauligk,Gerald Illerhaus,Uwe M. Martens,Jan Stoehlmacher,Harald Schmalenberg,Kim Barbara Luley,Nicole Prasnikar,Matthias Egger,Stephan Probst,Helmut Messmann,Markus Moehler,Wolfgang Fischbach,Jörg T. Hartmann,Frank Mayer,Heinz-Gert Höffkes,Michael Koenigsmann,Dirk Arnold,Thomas Kraus,Kersten Grimm,Stefan Berkhoff,Stefan Post,Elke Jäger,Wolf O. Bechstein,Ulrich Ronellenfitsch,Stefan Mönig,Ralf Hofheinz +27 more
TL;DR: Patients with limited metastatic disease who received neoadjuvant chemotherapy and proceeded to surgery showed a favorable survival, and the AIO-FLOT3 trial provides a rationale for further randomized clinical trials.
Journal ArticleDOI
Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie
Salah-Eddin Al-Batran,Joerg T. Hartmann,R.D. Hofheinz,N. Homann,Volker Rethwisch,Stephan Probst,Jan Stoehlmacher,Michael R. Clemens,R. Mahlberg,M. Fritz,G. Seipelt,M. Sievert,Claudia Pauligk,Akin Atmaca,Elke Jäger +14 more
TL;DR: Biweekly FLOT is active and has a favorable safety profile, and patients with measurable, metastatic adenocarcinoma of the stomach or esophagogastric junction and no prior chemotherapy receive docetaxel in combination with oxaliplatin as a 24-h infusion.